Skip to content
Review

Glial control of extracellular α-synuclein propagation in LRRK2 Parkinson's disease.

2026 · Advances in Immunology · Vol 171, pp. 215-246 · 0 citations
Medicine

TL;DR

This review synthesises current evidence on how mutations in Leucine-Rich Repeat Kinase 2 (LRRK2), the most common genetic cause of familial PD, fundamentally corrupt glial handling of extracellular α-synuclein and evaluates emerging therapeutic strategies targeting LRRK2 kinase activity, NLRP3 inflammasome activation, extracellular α-synuclein immunotherapy, and glial lysosomal enhancement.

View source

Similar papers

Open access Sep 2026

Spreading alpha-synuclein oligomers trigger astrocyte/microglial changes and astrocyte-glutamatergic neuron system dysfunction in an age-related manner

A model in which α-syn oligomer spreading, amplified by aging, simultaneously disrupts the astrocyte–glutamatergic neuron axis and drives microglia into a senescent DAM-like state is proposed, and candidate gene sets for both processes are provided for further investigation of glial dysfunction in PD.

Jaehyun LeeBae, Verena Bopp, Alicia Goreth et al. · 0 citations
Review Aug 2026

Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson’s Disease

It is proposed that a systems-level approach can be taken where PD is understood as a disease characterized by the imbalance in proteostasis, and potential treatment modalities include small molecules targeting lysosome function, CMA enhancers, gene therapy, and antibodies against extracellular α-synuclein.

Maryam Jabeen, Huma Hameed, Syed Muhammad Ahmad et al. · 0 citations
Open access Sep 2026

Cellular prion protein levels modulate nigrostriatal vulnerability to α-synuclein oligomers in Parkinson’s disease

PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.

Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al. · 0 citations
Open access Oct 2026

Human microglia clear intraneuronal α-synuclein aggregates by GPNMB-mediated trogocytosis

This study identifies a subtype of human microglia capable of removing intraneuronal aggregates and potential therapeutic targets and identifies a cluster of disease-associated microglia responsible for this beneficial phenotype and the Parkinson's disease GWAS candidate glycoprotein nonmetastatic melanoma protein B (G...

Hung-Ju Chueh, Antigoni Katsikoudi, Ana Aragón-González et al. · 0 citations
Review Open access Aug 2026

P2X7 receptor-dependent microglia-astrocyte coupling in Alzheimer's disease: from eATP sensing to synaptic and proteostatic failure

Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to transla...

Yiwen Li, Shi-Ming Liu, Jiao Lan · 0 citations
Open access Aug 2026

Aquaporin-4 mis-localization decreases glymphatic clearance of α-synuclein in an alpha-syntrophin knock out mouse model and promotes α-synuclein pathology and aggregate propagation.

Results indicate α-synuclein clearance and propagation are mediated by glymphatic function and that aquaporin-4 mis-localization observed in the presence of human synucleinopathy may contribute to the development and propagation of Lewy body pathology in conditions such as Lewy body dementia and Parkinson's disease.

Molly Braun, Matthew J. Simon, Jay Jang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.